(Q35549709)
English
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based th
scientific article published on 26 January 2015
Statements
1 reference
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based th (English)
1 reference
Karim Fizazi
1 reference
George Fountzilas
1 reference
Fred Saad
1 reference
David Agus
1 reference
Johann De Bono
1 reference
Robert Jones
1 reference
Stephane Oudard
1 reference
Eleni Efstathiou
1 reference
Ronald de Wit
1 reference
Felipe Melo Cruz
1 reference
Albertas Ulys
1 reference
Flavio Carcano
1 reference
Neeraj Agarwal
1 reference
Joaquim Bellmunt
1 reference
Daniel P Petrylak
1 reference
Shih-Yuan Lee
1 reference
Iain J Webb
1 reference
Bindu Tejura
1 reference
Niels Borgstein
1 reference
Robert Dreicer
1 reference
26 January 2015
1 reference
1 reference
33
1 reference
7
1 reference
723-731
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference